Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Simcere Pharmaceutical Group's average Book Value Per Share Growth Rate was 32.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Simcere Pharmaceutical Group was 67.90% per year. The lowest was 0.20% per year. And the median was 27.05% per year.
During the past 9 years, the highest P/B Ratio of Simcere Pharmaceutical Group was 16.90. The lowest was 1.70. And the median was 2.98.
Simcere Pharmaceutical Group (FRA:S2P) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Simcere Pharmaceutical Group Book Value per Share Related Terms
Simcere Pharmaceutical Group Book Value per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group Book Value per Share Chart
FRA:S2P vs ZTS, UTHR: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (FRA:S2P) has a Book Value per Share of €0.44 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Simcere Pharmaceutical Group and its competitors.
Is Simcere Pharmaceutical Group's Book Value per Share too high?
Simcere Pharmaceutical Group's current Book Value per Share is €0.44. Overall, Simcere Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's Book Value per Share compare to ZTS and UTHR?
Simcere Pharmaceutical Group's Book Value per Share of €0.44 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Simcere Pharmaceutical Group and its competitors. Simcere Pharmaceutical Group's current Book Value per Share is €0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.15, compared to a current price of €1.36 — trading 18.3% above its estimated fair value. The current Book Value per Share is €0.44. Simcere Pharmaceutical Group's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current Book Value per Share is €0.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.36 is trading 18.3% above its estimated GF Value™ of €1.15.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for FRA:S2P:
Book Value per Share: €0.44
GF Value™: €1.15 vs. price of €1.36 (18.3% above fair value)
No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
86GF Score
Get the complete analysis for FRA:S2P
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S2P has been successfully added to your 
